and MV is likely, for example when plasma vesicles are isolated by high speed (~100,000 g) 88 ultracentrifugation, we refer to them more broadly as EV. These EV are sometimes also 89 referred to as "exosome-like vesicles". 90
One of the characteristic markers of all EVs is the presence on the outer surface of 91 phosphatidyl serine (PS), due to loss of membrane asymmetry during blebbing (apoptotic 92 bodies) or budding (MV) and inward folding of the membrane during vesicle formation in 93 MVBs (exosomes). This can be identified by binding of labelled annexin V, a reagent often 94 used for flow cytometric analysis of apoptotic cells. However, more recently several groups 95 have identified MVs lacking phosphatidyl serine (PS) on the outer membrane, suggesting 96 that this is not essential for MV formation (Hou, et al. 2014; Larson, et al. 2012) . 97
Both exosomes and microvesicles characteristically carry a cargo, which they are able to 98 deliver to cells in remote locations. The cargo can include genetic material such as mRNA, 99 microRNA (miRNA) or even small amounts of DNA (Moldovan, et al. 2013) , and proteins 100 including transcription factors, cytokines and growth factors, have also been described. 101 Importantly, MVs also carry cellular receptors and transmembrane proteins on their surface 102 characteristic of the cells from which they were released. This aids in their identification but 103 also means that they can interact with specific target cells instigating signalling cascades via 104 receptor interactions (rececrine signalling -akin to cell-cell interactions) and also increasing 105 specificity of cargo delivery. On the other hand, exosomes are characteristically decorated 106 with markers including Alix, HSP70, and the tetraspanins CD9 and CD63, which may be 107 associated with beta-2 integrin binding and intercellular communication. Although these are 108 commonly used as markers of exosomes, they are not exclusive to exosomes and may be 109 found on other EVs. Furthermore, not all EVs express CD63 and different sub-populations of 110 exosomes may express different markers (Thery et al. 2009 ). It is important to consider that 111 exosomes do not necessarily express the same marker proteins as their parent cells. For 112 example, we found that the common endothelial marker CD144 is absent on exosomes from 113 human umbilical vein endothelial cells (HUVECs)( Figure 2) . Recent work has further defined 114 plasma EV and exosome surface marker expression by using extensive antibody profiling 115 which showed that exosomes can express surface membrane markers such as CD146, 116
CD4, CD3 and CD45 (Jorgensen, et al. 2015a ). There is some evidence that the protein and 117
RNA content of exosomes depends on the state of the source cell (de Jong, et al. 2012) . 118
The mechanism behind the formation of exosomes and selective packaging of proteins, 119 lipids and RNA is not completely understood but is gradually becoming revealed. The 120
Endosomal Sorting Complex Responsible for Transport (ESCRT) pathway does not seem to 121 have also been implicated in exosome biogenesis. For example, inhibitors of neutral 125 sphingomyelinase, an enzyme involved in ceramide production, inhibits exosome production 126 (Trajkovic et al. 2008) . Less well understood is the mechanism of exosome release. Certain 127 members of the Rab GTPase family are required for efficient release of exosomes, although 128 the exact members involved appears to depend on the cell type and experimental design, 129 and may reflect different subtypes of exosomes relating to the stage (early or late) of 130 endosome/MVB formation (Colombo et al. 2014) . 131
Purification of EVs from different bodily fluids 132
Although MVs and exosomes are produced by distinct mechanisms, their sizes overlap, and 133 most isolation protocols do not isolate a pure population. Therefore, in order to evaluate 134 published experiments it is important to understand what type of EV is most likely to be 135 isolated by different protocols. 136 A number of different protocols have been optimised for purification of different classes of 137
EVs from different sources, with isolation from plasma being the best described (reviewed 138 in (Lobb, et al. 2015; Witwer, et al. 2013) ). The isolation of EVs from blood requires its rapid 139 collection with an anti-coagulant -citrate is now generally advised ). The 140 most straightforward technique for isolation of EVs involves sequential steps of 141 centrifugation. After the collection of plasma by centrifugation at 1500 x g for 15 minutes, the 142 supernatant contains platelet-rich plasma and EVs (MVs and exosomes). This is followed by 143 a further centrifugation at 13,000 x g for 30 min to pellet the platelets, with the remaining 144 EVs in the platelet poor plasma (PPP) supernatant. PPP may be snap frozen at -80 °C until 145 analysis, or analysed immediately, using one of the methods outlined below. For further 146 purification the PPP can be centrifuged at 17,000 x g to pellet the larger MVs, which can 147 then be used for analysis. The supernatant can also be further ultracentrifuged at 100,000 x 148 g to pellet the remaining EVs (Thery, et al. 2006 Several companies produce reagents designed to precipitate exosomes from plasma or 158 tissue culture medium, though purity using these techniques is generally low, particularly 159 from plasma. Affinity purification using antibodies bound to columns or beads results in 160 much higher purity of EVs but by definition selectively purifies only EVs expressing the 161 marker protein of interest. Size-exclusion chromatography is increasingly popular as a 162 technique to purify exosomes, having been demonstrated to result in isolates relatively pure 163 of contaminating lipoproteins and protein complexes (Boing, et al. 2014; Welton, et al. 2015) . 164
Alternatively, new approaches on the horizon include the use of antibody arrays to directly 165 identify and quantify exosomes in body fluids bypassing the need for purification all together 166 (Jorgensen, et al. 2015b) . 167
Since the results of EV isolation procedures may vary, it is important to characterize the 168 particular population being used as much as possible. 169
Methods for the identification and characterization of EVs 170
The small size of EVs makes their identification a challenge, indeed until relatively recently 171 they were considered to be debris and not of any functional significance. Use of electron 172 microscopy enables accurate sizing of all different classes of EVs, and is the gold standard 173
to demonstrate presence of EVs, however this method is time consuming, not quantitative 174 and not suitable for phenotyping ( Figure 3 ; for review of methodology see (van der Pol, et al. 175 2010)). Other non-optical methods have been used, notably atomic force microscopy, which 176 enables accurate size detection and can also be used in after antibody labeling of vesicles 177 enabling phenotyping. Once again, however, the technique is time consuming and requires 178 concentration of the sample meaning that it is not quantitative. A number of optical methods 179 have been used for detection of EVs, the most widely reported of which is flow cytometry, 180 however detection is limited to particle sizes above ~200 nm, so exosome analysis is not 181 possible with standard configurations and techniques. However, recent exciting 182 developments have enabled direct visualization and characterization of microvesicles in 183 whole blood, platelet-rich and platelet-free plasma using Image stream technology 184 (Headland, et al. 2014) . 185
A number of sophisticated protocols have been described to differentiate MVs from 186 background noise during detection using this method, and standardised guidelines have now 187 been published for optimised collection of plasma for detection of MVs . 188 Techniques are being developed which may even allow the detection of individual exosomes 189 using dedicated flow cytometers with special labelling methods (Pospichalova, et al. 2015) . 190
An alternative and more widespread approach is to bind exosomes to carrier latex beads, 191 greater size discrimination compared to flow cytometry (down to below 50 nm diameter) and 209 so enable quantitation of exosomes and smaller MV more efficiently (cost and time) than by 210 EM or atomic force microscopy, however, they are limited by lack of multiple laser 211 capabilities to enable accurate phenotyping, as well as sometimes requiring lengthy 212 purification protocols to ensure that only exosomes are quantified. Importantly, they cannot 213 distinguish EVs from other particulate matter such as protein aggregates, so confirmatory 214 techniques are required to validate EV presence. Raman spectroscopy has also been used 215 to define EV populations. This is a highly sensitive technique for analysis of the biochemical 216 composition of EVs without labelling, and can provide quantitative data, however it is very 217 time consuming. Direct detection of marker proteins on exosomes is challenging using these 218
techniques. 219

Extracellular vesicles can transfer proteins and RNA 220
The field of EV research was greatly invigorated by the demonstration that they are able to 221 deliver proteins and RNA to recipient cells. The first evidence for this was obtained in 222 can also deliver mRNA (Skog, et al. 2008) . 229
Exosomes can also deliver molecules into the membrane of recipient cells. This appears to 230 be part of their normal function in helping to establish morphogen gradients during 231 development. For example, exosomes can transfer the Notch ligand Delta-like 4 (Dll4) 232 between endothelial cells, where it is incorporated into the membrane of the target 233 endothelial cells, and inhibits Notch signalling altering angiogenesis (Sheldon, et al. 2010) . 234
Interestingly, some cytoprotective proteins have been shown to be transferred between 235 cells. αB crystallin is secreted from human retinal pigment epithelium in exosomes, and 236 taken up by adjacent photoreceptors, protecting them from oxidative stress (Sreekumar, et 237 al. 2010) . 238
In a seminal paper, Valadi et al, were first to show that exosomes can also transfer mRNA 239 and miRNA between cells (Valadi, et al. 2007 ). In this study, mast cells were demonstrated 240 to transfer functional mRNAs between cells that were subsequently translated. Importantly 241 when exosomes were pre-treated with RNAse and trypsin, the effect was no longer 242 observed, demonstrating that the mRNA was protected within the vesicles and not simply 243 associated or co-purified. 244
The profile of miRNAs contained within exosomes appears to depend on the cell type of 245 origin. The miRNA profile is different in exosomes released from C2C12 myoblasts 246 compared with those released by C2C12 cells once they have differentiated into myotubes 247 (Forterre, et al. 2014 ). The miRNA profile within exosomes was also found to differ from the 248 parent C2C12 cells, which indicates that there is selective sorting of miRNA into exosomes 249 (Forterre et al. 2014). The mechanism for this is only beginning to be unravelled, but 250 appears to involve recognition of particular sequence motifs by sumoylated heterogeneous There is also evidence that exosomes are used by some cells in the heart to communicate 256 to each other. Cardiac fibroblasts secrete exosomes that are enriched in specific miRNAs, 257
including miR-21-3p. Intriguingly, this particular miRNA is a "passenger strand" miRNA 258 which normally undergoes intracellular degradation and was therefore believed to be non- including atherosclerosis (Diamant et al. 2002) . Increased numbers of MV have also been 292 linked to obesity (Stepanian, et al. 2013 ). Interestingly, a significant reduction in MV 293 numbers has been described after calorific restriction or bariatric surgery in these patients 294 (Cheng, et al. 2013 ). Increased EVs are also a hallmark of CVD including atherosclerosis 295 The role of chronic inflammation in progression of CVD and CMD has been highlighted in a 298 number of studies (reviewed in (Hansson, et al. 2015) ; (Lindhardsen, et al. 2015) ) and 299
circulating EVs are increased in many inflammatory conditions (e.g. (Daniel, et al. 2006 ; We have recently shown that EVs induced by long term feeding of a high fat diet in a rat 307 model of insulin resistance and T2DM were able to induce VCAM-1 adhesion molecule 308 expression and ROS production in rat cardiac endothelial cells in vitro (Heinrich, et al. 2015) . 309
The same factors that increase the risk of cardiometabolic disease are also risk factors for 310 polycystic ovary syndrome (PCOS) (Daskalopoulos, et al. 2015) , the most common 311 endocrine disorder in women aged 18-44, affecting up to 10% of the population, and which 312 leads to reduced fertility (Teede, et al. 2010 ). Several studies have now shown that in 313 accordance with these increased risk factors, PCOS patients have increased circulating 314 levels of EVs, particularly pro-coagulant platelet MVs (Koiou, et al. 2011; Koiou, et al. 2013) . 2012). In this study, EV were purified by centrifugation at 20,500 g for 1 h, resulting in 369 vesicles that were mostly between 60 and 130 nm. 370
In some cases, exosomes can also suppress hyperproliferative pathways such as those that 371 contribute to hypoxia-induced pulmonary hypertension. Here, the beneficial effect of 372 mesenchymal stromal cells was shown to be mediated by the release of exosomes which 373 suppressed hyperproliferative pathways including those mediated by STAT3 and the miR-17 374 superfamily, in addition to increasing lung levels of miR-204 (Lee, et al. 2012) . 375
Recently, pressure overload or stretch was shown to cause the release from cardiomyocytes 376 of exosomes containing functional angiotensin II type 1 receptors, which are able to be 377 transferred to skeletal muscle, mesenteric resistance vessels and cardiomyocytes, 378 conferring responsiveness to angiotensin II (Pironti, et al. 2015) . This exciting data suggests 379 that exosomes may contribute to the in vivo tissue distribution of cell surface receptors such 380 as angiotensin II, with functional consequences for the cardiovascular system. 381
The role of EVs in coagulopathies 382
When EVs were first described by Peter Wolf they were referred to as "platelet dust" (Wolf 383 1967) because they were thought not to be functionally significant. Despite there being some 384 surface of activated platelets and become incorporated into the clot (Falati, et al. 2003) . 392
Other receptors including glycoprotein IIb/IIIa (Sommeijer, et al. 2005) , factor VIII, factor Va 393 (Nomura, et al. 1993 ) and protein disulphide isomerase (Raturi, et al. 2008 ) may also be 394 present on the surface of EVs and participate in clot formation and thrombosis. 395
In addition to hyperglycemia, hyperinsulinemia can cause an increase in procoagulant TF- but also due to their diminished ability to support endothelial function. 420
EVs as a potential therapy for cardiometabolic disease 421
The heart is essentially terminally differentiated, meaning that there is very little division of 422 cardiomyocytes after injury (e.g. IR), and instead those that remain tend to undergo a 423 therapy has been intensively investigated for a number of years, however, the results of this 425 approach have been largely disappointing. Some improvements in cardiac function have 426 been observed after stem cell therapy, although this is generally acknowledged to occur in 427 the absence of new cardiomyocyte formation. Interestingly, similar levels of benefit could 428 also be obtained experimentally after injecting medium that had been conditioned by stem 429 cells. It was therefore proposed that stem cells release cytokines, growth factors and other 430 proteins in a "paracrine" manner to improve survival and function of cardiomyocytes (Kim, et does not appear to be restricted to exosomes, since microvesicles derived from human adult 446 mesenchymal stem cells were also able to protect the kidney against ischaemia and 447 reperfusion injury (Gatti, et al. 2011) . 448
MSC are not the only type of stem cell that has been shown to release exosomes with 449 beneficial cardiovascular effects. Intramyocardial injection of exosomes from murine cardiac 450 progenitor cells (CPCs) reduced apoptosis after ischaemia and reperfusion (Chen, et al. 451 2013) . In this study, however, exosomes were isolated by precipitation with polyethylene 452 glycol (PEG) (Chen et al. 2013 ), which raises some uncertainty about the effects that the 453 PEG might have itself. In another study EVs were isolated from CPCs derived from atrial 454 appendage explants from patients undergoing heart valve surgery (Barile, et al. 2014) . 455
Injection of these CPCs-EVs into the hearts of rats subject to permanent coronary artery 456 ligation reduced cardiomyocyte apoptosis and scar size, increased the amount of viable 457 tissue in the infarct area, increased blood vessel density, and prevented the impairment of 458 isolated from CPCs that had been exposed to hypoxia for 12 h improved cardiac function 462 and also reduced fibrosis 21 days (Gray, et al. 2015) . The exosomes released after hypoxia 463 had an altered miRNA content, and co-regulated miRNA with a beneficial profile were 464 identified (Gray et al. 2015) . Although cardiac endothelial cells and fibroblasts took up 465 fluorescently stained exosomes in vitro, uptake was minimal in primary rat cardiomyocytes 466 (Gray et al. 2015 ), suggesting either that they deliver miRNA directly to the former cells 467 types, or that they interact with surface receptors on cardiomyocytes without delivering 468 miRNA intracellularly. Thus, the exact mechanism of functional benefit conferred by CPC-469
EVs remains unclear. 470
When a nonviral mini-circle plasmid carrying HIF1, a transcription factor that mediates 471 adaptive responses to ischemia, was delivered into the endothelium of ischemic mouse 472 myocardium, these cells were found to release exosomes with a higher content of miR-126 473 and miR-210. These exosomes could be taken up by CPCs administered to the heart, 474
leading to the activation of pro-survival kinases and to a switch towards glycolysis. This 475 resulted in them having an increased tolerance against hypoxic stress (Ong, et al. 2014) and 476 suggests the interesting possibility that endothelial cells can support CPC survival by 477 exosomal transfer of miRNA. 478
An attractive aspect of using EVs for therapy is the potential for altering their cargo to 479 augment their protective capabilities. In a study by Mackie et al, CD34 + cells or their 480 exosomes showed no benefit after injection into ischaemic mouse hearts. However, CD34 + 481 cells were then genetically modified to to express the sonic hedgehog (Shh) protein, in order 482 to enhance the angiogenic quality of CD34 + cells. When CD34 + Shh cells were injected into 483 the infarct border zone in mice, infarct size was reduced, border zone capillary density was 484 increased, and ventricular dilation and cardiac function were improved 4 weeks later 485 (Mackie, et al. 2012) . In vitro studies in cells were performed to demonstrate that Shh was 486 released from the CD34 + Shh cells in exosomes, and could be transferred to recipient cells 487 and (modestly) activate transcription. Injection of the exosomes from CD34 + Shh cells had 488 the same benefit, though exosomes from CD34 + cells wihout Shh showed no benefit 489 (Mackie et al. 2012) . 490
Strikingly, it has been shown that there are on the order of 10 10 EVs per ml present in the 491 blood of all individuals, after isolation using the technique of differential ultracentrifugation, 492 (Caby et al. 2005) , and these could potentially be continually delivering different miRNA or 493 receptor-ligand mediated signals to the heart. This possibility was addressed by isolating 494 plasma exosomes from rats or healthy individuals by differential ultracentrifugation and 495 testing whether they were cardioprotective in in vitro, ex vivo and in vivo models of IR 496 (Vicencio, et al. 2015) . Indeed, exosomes from plasma were strongly cardioprotective, 497 activating the cardioprotective ERK1/2 kinase and reducing infarct size (Vicencio et al. 498 2015) . Plasma exosomes were similarly protective in an isolated perfused rat heart model 499 and in primary cardiomyocytes, suggesting a direct effect of the exosomes at the plasma 500 membrane level, although interestingly exosomes did not appear to be taken up by the 501 cardiomyocytes but they were endocytosed by endothelial cells (Vicencio et al. 2015) . This 502 study also showed that the number of exosomes in the plasma was increased by short (5 503 min) cycles of limb IR. This manipulation is under investigation of a means of inducing 504 protection of the heart and other organs via a phenomenon known as "remote ischaemic 505 preconditioning (RIC)" (Hausenloy and Yellon 2008) . As yet, the mechanism of RIC is 506 unknown although evidence for several mediators has been presented, including SDF-1α 507
and Il-10 (Cai, et al. 2012; Davidson, et al. 2013) . As vehicles able to deliver multiple signals 508 between cells, EVs had been proposed as possible candidates for carriers of the 509 cardioprotective factor released by RIC (Yellon and Davidson 2014) . A study by Giricz et al. 510 suggested that this may be the case, since RIC was not effective when EVs were removed 511 from medium containing the factor (Giricz, et al. 2014 ). However, in a dose-response 512 experiment conducted using primary adult rat cardiomyocytes the EVs released after RIC 513
were found not to be significantly more protective that exosomes from baseline (Vicencio et 514 al. 2015) . 515
On the other hand, the observation that plasma EVs themselves were cardioprotective is 516 important and may suggest that they signal continuously to the heart, modulating the 517 protective state. Protection was shown to involve HSP70 in the exosome membrane, which 518 binds to TLR4 on cardiomyocytes, activating ERK1/2, p38MAPK and downstream 519 phosphorylation of the small heat shock protein HSP27 (Vicencio et al. 2015) . TLR4 is part 520 of the innate immune system, and strong activation by its ligands from bacteria leads to a 521 cell damage response and can cause cell death. However, mild activation is known to be 522 protective (Mathur, et al. 2011; Zhang, et al. 2013 Increased MVs in plasma can be observed in patients with insulin resistance, T2DM, 533 atherosclerosis and also after stroke or myocardial infarct. MVs have been also described as 534 mediators of inflammation and to be involved in the pro-coagulant actions of platelets. The 535 protein or RNA cargo of EVs offers additional potential not only for their use as biomarkers 536 but also for their use as vehicles for delivering bioactives. As such, they offer the capability 537 of delivering multiple signals to target tissues. Stem cells are the best-explored example of 538 cells that deliver miRNA via exosomes with beneficial effects on the heart, kidneys and the 539 endothelium. Exosomes and MVs have also been implicated in protecting the heart from 540 infarction and have been proposed as potential mediators of ischaemic conditioning. EVs 541 therefore represent one of the most exciting and promising research areas for the endocrine 542 community. However, there is still much left to understand regarding the mechanisms of EV 543 formation and their specific targeting to a selective tissue. 
Figure 2
The endothelial cells marker CD144 is absent from exosomes isolated from HUVEC endothelial cells (A), despite being detectable on the parent cells (B). HUVEC cells or HUVEC exosomes bound to 4 µm beads were labelled with anti-CD144 and fluorescent secondary antibody, before fluorescent detection using a BD AccuriC6 flow cytometer. 
